Abstract
Actinobacteria have proven themselves as the major producers of bioactive compounds with wide applications. In this study, 35 actinobacteria strains were isolated from soil samples collected from the Himalayan mountains region in Pakistan. The isolated strains were identified by polyphasic taxonomy and were prioritized based on biological and chemical screening to identify the strains with ability to produce inimitable metabolites. The biological screening included antimicrobial activity against Staphylococcus aureus, Micrococcus luteus, Salmonella enterica, Escherichia coli, Mycobacterium aurum, and Bacillus subtilis and anticancer activity using human cancer cell lines PC3 and A549. For chemical screening, methanolic extracts were investigated using TLC, HPLC-UV/MS. The actinobacteria strain PU-MM93 was selected for scale-up fermentation based on its unique chemical profile and cytotoxicity (50–60% growth inhibition) against PC3 and A549 cell lines. The scale-up fermentation of PU-MM93, followed by purification and structure elucidation of compounds revealed this strain as a promising producer of the cytotoxic anthracycline aranciamycin and aglycone SM-173-B along with the potent neuroprotective carboxamide oxachelin C. Other interesting metabolites produced include taurocholic acid as first report herein from microbial origin, pactamycate and cyclo(L-Pro-L-Leu). The study suggested exploring more bioactive microorganisms from the untapped Himalayan region in Pakistan, which can produce commercially significant compounds.
Original language | English |
---|---|
Pages (from-to) | 3044-3057 |
Number of pages | 14 |
Journal | Current Microbiology |
Volume | 78 |
Issue number | 8 |
DOIs | |
State | Published - Aug 2021 |
Bibliographical note
Publisher Copyright:© 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Funding
This work was supported by Higher Education Commission (HEC) Pakistan grant (HEC-NRPU Project 2121). The work was also supported by National Institutes of Health grants R24 OD21479 (SRV, JST), R01 GM115261 (JST), the Center of Biomedical Research Excellence (COBRE) in Pharmaceutical Research and Innovation (CPRI, NIH P20 GM130456), the University of Kentucky College of Pharmacy, the University of Kentucky Markey Cancer Center and the National Center for Advancing Translational Sciences (Grant Nos. UL1TR000117, UL1TR001998). We thank the College of Pharmacy NMR Center (University of Kentucky) for NMR support.
Funders | Funder number |
---|---|
Center of Biomedical Research Excellence | |
HEC-NRPU | 2121 |
University of Kentucky | |
National Institutes of Health (NIH) | R24 OD21479, P20 GM130456 |
National Center for Advancing Translational Sciences (NCATS) | UL1TR001998, UL1TR000117 |
University of Kentucky Markey Cancer Center | |
Japan Science and Technology Agency | R01 GM115261 |
Higher Education Commission, Pakistan |
ASJC Scopus subject areas
- Microbiology
- Applied Microbiology and Biotechnology